News

Reciprocal risks found between psoriatic disease and uveitis


 

FROM JAMA DERMATOLOGY

References

Researchers have uncovered a bidirectional relationship between psoriatic disease – psoriasis and psoriatic arthritis – and uveitis, with either condition significantly increasing the risk of the other.

A Danish nationwide cohort study of 74,129 individuals with psoriasis, including 6,735 with psoriatic arthritis, showed that patients with mild psoriasis had a 38% increased risk of uveitis, while those with psoriatic arthritis had a 2.5-fold increase in risk and those with psoriatic spondylitis had a greater than eight-fold increased risk, according to a paper published online in JAMA Dermatology.

Elsevier 2009

There was a nonsignificant increase in the risk of uveitis in patients with severe psoriasis, but this failed to reach significance because of the small number of patients.

Similarly, patients with uveitis had a 59% greater risk of mild psoriasis, a twofold greater risk of severe psoriasis, a nearly fourfold increase in the risk of psoriatic arthritis, and an eightfold increase in the risk of psoriatic spondylitis (JAMA Dermatol. 2015 July 29 doi: 10.1001/jamadermatol.2015.1986).

The authors suggested that an increased focus on eye symptoms in patients with psoriasis and psoriatic arthritis and on skin and joint symptoms in patients with uveitis may be appropriate.

“The bidirectional relationship between psoriasis and psoriatic arthritis and uveitis suggests a shared pathogenic pathway, and increased systemic inflammation may contribute to the observed relationship,” wrote Dr. Alexander Egeberg of Pfizer and his coauthors. Dr. Egeberg was at the University of Copenhagen, Hellerup, when the study was conducted.

The study was supported by Pfizer, the LEO Foundation, and the Novo Nordisk Foundation. One author is employed by Eli Lilly. No other conflicts of interest were declared.

Recommended Reading

WCD: IL-23p19 inhibitors yield ‘promising’ psoriasis results
Psoriatic Arthritis ICYMI
WCD: Secukinumab shows effectiveness for nail, palmoplantar psoriasis
Psoriatic Arthritis ICYMI
EULAR: Panel targets six rheumatic disease comorbidities
Psoriatic Arthritis ICYMI
EULAR’s psoriatic arthritis recommendations gain new drugs
Psoriatic Arthritis ICYMI
Guselkumab prevails in phase II psoriasis trial
Psoriatic Arthritis ICYMI
WCD: Touch avoidance is a new dimension of psoriatic impairment
Psoriatic Arthritis ICYMI
Secukinumab proves successful against psoriatic arthritis in FUTURE 2 trial
Psoriatic Arthritis ICYMI
GRAPPA initiatives continue to chart the way for psoriasis, psoriatic arthritis
Psoriatic Arthritis ICYMI
Apremilast response durable at 52 weeks
Psoriatic Arthritis ICYMI
PsA disease activity and treatment success defined
Psoriatic Arthritis ICYMI